Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.15 CAD | 0.00% | +11.11% | +87.50% |
03-26 | Marvel Biosciences Corp. Reports Earnings Results for the Second Quarter and Six Months Ended January 31, 2024 | CI |
03-25 | Marvel Biosciences Announces Positive Interim Results For MB-204 | MT |
Sales 2022 | - | Sales 2023 | - | Capitalization | 3.18M 4.38M 255M |
---|---|---|---|---|---|
Net income 2022 | -2M -2.75M -160M | Net income 2023 | -2M -2.75M -160M | EV / Sales 2022 | - |
Net cash position 2022 | 593K 816K 47.46M | Net Debt 2023 | 443K 610K 35.47M | EV / Sales 2023 | - |
P/E ratio 2022 |
-1.09
x | P/E ratio 2023 |
-1.38
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 70.15% |
1 week | +11.11% | ||
1 month | -6.25% | ||
3 months | +42.86% | ||
6 months | +114.29% | ||
Current year | +87.50% |
Managers | Title | Age | Since |
---|---|---|---|
Joseph Matheson
CEO | Chief Executive Officer | - | 13/06/21 |
Harry Nijjar
DFI | Director of Finance/CFO | 36 | 31/01/22 |
Mark Williams
PSD | President | 52 | 13/06/21 |
Members of the board | Title | Age | Since |
---|---|---|---|
S. Smallbone
BRD | Director/Board Member | - | 14/02/22 |
Joseph Matheson
CEO | Chief Executive Officer | - | 13/06/21 |
Mark Williams
PSD | President | 52 | 13/06/21 |
Date | Price | Change | Volume |
---|---|---|---|
30/04/24 | 0.15 | 0.00% | 7 550 |
29/04/24 | 0.15 | +3.45% | 10,500 |
26/04/24 | 0.145 | +7.41% | 158,571 |
25/04/24 | 0.135 | 0.00% | 4,000 |
24/04/24 | 0.135 | 0.00% | 6,024 |
Delayed Quote Toronto S.E., April 30, 2024 at 06:22 pm
More quotes1st Jan change | Capi. | |
---|---|---|
+87.50% | 4.37M | |
+0.23% | 42.86B | |
+11.78% | 42.74B | |
+44.30% | 41.36B | |
-6.20% | 27.68B | |
+5.33% | 25.15B | |
-24.15% | 18.63B | |
+27.27% | 12.37B | |
-3.80% | 11.92B | |
+7.13% | 11.21B |
- Stock Market
- Equities
- MRVL Stock